Perivascular lymphocyte infiltrates, reactive astrocytes, and activated microglia are hallmarks of the cellular changes seen in active lesions in the chronic CNS demyelinating disease multiple sclerosis (MS). The majority of the perivascular lymphocytes in MS lesions are T cells, possibly representing a restricted cellular immune response which might be specific for CNS antigens including myelin basic protein (Oksenberg et al., 1993) . While multiple immune effector mechanisms are postulated to mediate tissue injury in MS, entry of T cells into the CNS parenchyma is one of the early indicators of disease pathology. Whether initial or subsequent sensitization to CNS antigens occurs in the periphery and/or in the CNS is unresolved. Activated T cell blasts, regardless of MHC class II restriction or antigen specificity, have an enhanced capacity to cross the blood-brain barrier and enter the CNS (Hickey et al., 1991) . Once inflammation is initiated in the CNS, the recruitment of nonactivated T cells could occur. Whether T cells migrating or recruited to the CNS are subsequently activated or restimulated to continue to proliferate, or instead become anergic or apoptotic Pender et al., 1992) , may depend both upon the brain microenvironment (Sloan et al., 1992) and the putative CNS antigen-presenting cells (Wekerle et al., 1986) .
Based upon early in situ and in vitro studies, both astrocytes and microglia have been implicated as resident CNS cells capable of presenting antigen to MHC class II restricted CD4+ T cells. While astrocytes have been reported to express MHC class II antigens in CNS disease (Traugott and Raine, 1985a; Traugott et al., 1985b; Lee et al., 1990) microglia are considered to be the major cell type expressing MHC class II antigens in "normal" individuals (Mattiace et al., 1990; Graeber et al., 1992; Sasaki et al., 1992; Sedgwick et al., 1993) and in MS lesions (Hayes et al., 1987; Boyle et al., 1990; Ulvestad et al., 1994b) .
Rodent astrocytes Fierz et al., 1985; Massa et al., 1987) and microglia (Frei et al., 1987; Matsumoto et al., 1990) can express MHC class II antigens in vitro and have been demonstrated to function as APCs capable of supporting the continued proliferation of Ag-specific CD4+ T cell lines. Recently the ability of highly enriched rodent astrocyte cultures or astrocytes cultured under "in situ mimicking conditions" to present antigen have been questioned Weber et al., 1994) . Investigating the differences in phenotype and function between rodent and human glial cells, the establishment of glial cell cultures from fetal human brain has been investigated (Shein, 1965; Elder and Major, 1988) . We have initiated similar cultures from human fetal brain, but have also established cultures from adult human brain and assessed the antigen presentation capacity of glial cells from these cultures (Yong et al., 1991 Williams et al., 1992) . We have previously demonstrated that adult human brain-derived microglia can present recall antigen to freshly derived autologous CD4+ T cells (representing a 2" T cell response) (Williams et al., 1992) and present antigen to immediately ex viva bloodderived allogeneic CD4+ T cells in an MLR (representing a 1" T cell response) (Williams et al., 1993) . Consistent with previous observations using fetal rodent astrocytes , we found that fetal human astrocytes expressing MHC class II antigens were unable to initiate a similar CD4+ T cell response (Williams et al., 1993) .
To define a cellular basis for the differences in the antigen presentation capacity between astrocytes and microglia, we have previously 'documented that in vitro both cell types express MHC class II, LFA-3, and ICAM-I molecules constitutively, and that microglia additionally express LFA-1 and B7/BB-1, particularly following IFNy stimulation (Williams et al., 1993 (Williams et al., , 1994 . In this study, we observed that the addition of as few as l-5 X lo3 microglial cells to the non-priming astrocyte 1" MLR could restore a significant CD4+ T cell response. We further demonstrate that the addition of as little as 1 U/ml of human rIL-la, a cytokine expressed by microglia but not by astrocytes as determined by reverse transcriptase-polymerase chain reaction (RT-PCR) and cytokine bioassays, reversed the inability of astrocytes to present antigen to freshly isolated human peripheral blood-derived CD4+ T cells. These data suggest that purified human astrocytes, without "contaminating" microglia, are unable to present antigen and activate freshly derived CD4+ T cells in vitro. In the CNS, however, astrocytes may be able to present antigen and initiate immune responses with the cooperative effect of microglia.
Materials and Methods Source of glial cells
Adult human brain tissue served as the source of microglia and was obtained from surgical resections, carried out to ameliorate non-tumorrelated intractable epilepsy (N = 7 patients) (aged 1845 years). Tissues used were derived from regions requiring resection to reach the precise epileptic focus, and were distant from the main electrically active site. Fetal human CNS tissues served as the source of astrocytes and were prepared from 8-12.week-old specimens (N = 8) following Medical Research Council (MRC) of Canada approved guidelines.
Glial cell preparations
Adult. Our method for preparing adult human glial cell cultures has been previously described lYoni et al., 1991, 7992; Williams et al., 1992) . Brieflv. tissues were treated with trvDsin 10.25%) and DNase 150 p,g/&l) folIoled by a percoll gradient cehirifugation (Pharmacia Lb Biotechnology, Uppsala, Sweden) at 15,000 RPM for 30 min. A mixed, dissociated glial cell suspension was then suspended in culture medium consisting of Eagle's MEM supplemented with 5% FCS, 0.1% glucose, and 20 yglml gentamicin, and seeded into 25 cm2 tissue culture flasks (Nunc, Burlington, Ontario). The following day, oligodendrocytes remained floating and were removed. Remaining adherent cells consisting of astrocytes and microglia were allowed to develop morphologically for 7 d. At this time the less adherent astrocytes were then floated off by rotary shaking for 5 hr at 150 'pm. Microglia were detached by incubation of cells using 0.25% trypsin and DNase (50 pg/ml) at 37°C for 15 min, and seeded either into 96-well microtiter plates or onto Aclar fluorocarbon-coated coverslips (Dr. S. Kim, Vancouver, BC) previously coated with 10 kg/ml poly-L-lysine.
Fetal. Fetal cultures were prepared by carefully stripping CNS material of meninges and blood vessels, mechanically dissociating the tissue with scalpel blades followed by treatment with trypsin (0.25%) and DNase (50 kg/ml) at 37°C for 45 min. Dissociated tissue was then passed through a 130 pm nylon mesh, washed 2X in PBS, and cells were plated directly onto poly+lysine-coated plastic culture dishes in culture medium. Cultures consisting of astrocytes, neurons, and sparse microglia were split when confluent (approximately every 2 weeks). Experiments were conducted after the second or third cell passage when fetal neurons and microglia were no longer apparent in culture. Similar to microglia, astrocytes were seeded into 96.well plates at a density of 2 X lo4 cells per well.
Purity of microglia and astrocyte cultures was determined by immunostaining with anti-CD 11 c (Leu-MS, 1: 10) (Beckton-Dickinson, San Jose, CA) or rabbit anti-GFAP Ab (1: 100) (Dako, Westchester, PA) followed by goat anti-mouse Ig-Rh (1:150) (Cappel, Lexington, MA) or goat anti-rabbit Ig-FITC (1: 150) (Cappel). Prior to staining for GFAP, cells on coverslips were fixed with acid alcohol (5% glacial acetic acid: 95% absolute ethanol, v/v). Proportions of immunostained cells were assessed by counting using a fluorescence microscope, or by FACScan analysis (Beckton Dickinson).
CD4' T-lymphocyte preparations
Mononuclear cells (MNC) were isolated by Ficoll-Hypaque density centrifugation from heparinized peripheral blood samples obtained from young adult volunteers. Total T cells were isolated by rosetting MNC with S-(2-aminoethyl) isothiouronium bromide hydrobromide (AET)-treated sheep red blood cells (Williams et al., 1992) . The rosette-positive T cells (E' ) were further purified as described below. Mononuclear cells that did not rosette (Em), consisting of B cells and monocytes, were irradiated (2500 rad) and used in some MLR assays as controls. CD4+ T cell populations were prepared by incubating total T cells with anti-CD8 monoclonal antibodies (prepared from OKT8 hybridoma obtained from ATCC, Rockville, MD), followed by the addition of rabbit complement (Cedarlain Laboratories, Hornby, Ontario). Cells were cultured in medium consisting of RPM1 supplemented with 5% human AB serum (Pel-Frez, Brown Deer, WI), 2.5 kg/ml penicillin, and 2.5 bglml streptomycin. The purity of the CD4' T cells, assessed by immunostaining with fluorescein-labeled anti-CD8 mAb (Leu2) (Beckton-Dickinson) and phycoerythrein-conjugated anti-CD4 mAb (Leu 3a) (Beckton-Dickinson), and analyzed by FACScan (Beckton-Dickinson), was >96%.
Functional CD4+ T cell assays
Primary MLR (1" MLR). For these studies 1 X lo5 CD4+ T cells from at least two different donors per experiment were placed into individual wells of flat-bottom microtiter plates in which fetal astrocytes had been previously seeded at confluence (2 X lo4 cells per well). Astrocytes were irradiated in the 96.well plates with 2500 rads (AECL Gamma Cell 1000 Irradiator) prior to the addition of CD4+ T cells. Fetal astrocytes were used under basal culture conditions and following stimulation with human rIFNy (100 U/ml) (Boehringer Mannheim, Germany) and TNFa (100 U/mL) (Genzyme, Boston, MA) 48 hr prior to lymphocyte coculture. Culture wells were washed extensively prior to all T cell assays. The mixed lvmphocvte reaction was carried out for 5 d.
To assess dD4+ T cell profifeiation, the cells were pulsed for 5 hr with 3H-TdR (1 LCi oer well) (ICN Flow Laboratories. Mississauga. OT). harvested, ahd thk counts'determined using a p liquih scintillati&'co& ter (LKB, Fisher, Montreal, PQ). Results are expressed as mean counts per minute (cpm) of triplicate wells.
Initial titration studies had been undertaken to determine at which seeding concentrations microglia and astrocytes stimulate CD4+ T cells in an allogeneic MLR. For these studies, irradiated microglia (2500 rads) and astrocytes, and nonrosetting mononuclear cells (Em), consisting of monocytes and B lymphocytes, were seeded into 96.well flatbottom microtiter plates aLseeding densities ranging from lo* to 1 X lo5 cells per well. To these, 1 X lo5 allogenic CD4+ T cells (from two donors per experiment) were added as described below.
Secokdary &fLR (2" MLR). For these studies 1 X 10' freshly isolated CD4+ T cells were coincubated with confluent bulk astrocvte cultures in 25 cm2 flasks with human rIL-2 (50 U/ml) (Genzyme). Cells were incubated for 5 d, at which time lymphocytes were recovered and then introduced back into an MLR with sister fetal astrocyte cultures as described above.
Cytokine analysis
Using the reverse transcriptase-polymerase chain reaction (RT-PCR), cytokine gene expression was assessed using enriched microglia and astrocyte cultures, and brain biopsy specimens (taken from the same material used to establish glial cell cultures) that had been snap frozen in liquid nitrogen. Some astrocyte cultures were preincubated with IFNy for 24 hr prior to RNA extraction. Total RNA was isolated using the guanidinium isothiocyanate-phenol-chloroform method (Chomczynski et al., 1987) . Contaminating DNA was removed by treatment with 1 U RNase-free DNase (RQl DNase, Promega) for 30 min at 37°C in 40 mM Tris HCl, pH 7.9, 10 mM NaCl, and 6 mM MgCl,. The RNA was then reextracted with phenol, ethanol precipitated, and stored at -20°C.
RNA (0.2-0.5 ug) was reverse transcribed and amplified in a singlestep process as described by Singer-Sam et al. (1991) , with the following modifications:
5 U AMV reverse transcriptase (GIBCO), 40 U RNA-guard (Pharmacia, Uppsala, Sweden), 12.5 U TAQ DNA polym&ase (GIBCO), 50 ~M-~NTPs (Pharmacia), 50 pM primers (Sheldon Biotechnology, Montreal, PQ), and 0.5 pCi of ol-32P-dATP (Amersham, Arlington Heights, IL). The total reaction volume of 50 )~l was then overlaid with 100 pl of heavy mineral oil. Samples were placed in a thermocycler (Cetus, Perkin Elmer, Norwalk, CT) for 15 min at 5O"C, followed by 20 cycles of 94°C for 1 min, 55°C for 2 min, and 72°C for 2.5 min. Following amplification, 25 ~1 of each sample was electrophoresed on a 10% nondenaturing polyacrylamide gel which was then dried under vacuum and visualized by autoradiography.
The sequence of the primers used was previously determined by others to be specific for the cytokine of interest. The oligonucleotide sequences are as follows: IL-la forward (F) 5'.GTCTCTGAATCAGA AATCCTT and reverse (R) 5'-CATGTCAAATTTCACTGCTICA TCC (Wang et al., 1989) , IL-6 F 5'-CCAAGAATCTAGATGCAAT AAA and R 5'-GCCAATTAACAACAACAATCTG (Hirano et al., 1986) , TNF F S'CCCTCAAGCTGAGGGGCAGCTCCAG and R 5'-GGGCAATGATCCCAAAGTAGGGGGGACCTG (Wang et al., 1989) . Primers specific for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were also employed as controls for RNA loading. The sequence for this set of primers is as follows: F 5'-CCATGGAGA AGGCTGGGG and R 5'-CAAAGTTGTCATGGATGATGACC (Atari et al., 1984) .
Cytokine bioassays
Assay for IL-l and IL-2. IL-I was determined in a two-stage assay by the IL-l-responsive mouse T cell line EL-4 6.1 clone NOB-l (Gearing et al., 1987) and the IL-2dependent mouse T cell line HT-2. The EL-4 cells produce IL-2 in response to IL-l stimulation, and the IL-2 production was measured by the proliferation of the IL-2-dependent HT-2 cells. Serial dilutions of samples were added in duplicate to flat-bottom 96-well microtiter plates, and the volume adjusted with medium to 100 pi/well. The medium utilized was RPM1 1640 supplemented with 0.1 mg/ml L-glutamine, 40 pg/ml gentamicin, 10% FCS, and 25 pM 2-mercaptoethanol. The EL-4 cells were washed once in Hank's balanced salts (HBSS) (GIBCO, Paisley, UK), resuspended in medium, and incubated at 2 X IO5 cells/well, producing a final volume of 200 ul per well. After 24 hr of incubation, 100 p,l of supernatant was transferred from each well into a replicate microtiter plate. The HT-2 cells were washed three times in HBSS, resuspended in medium, and distributed to the microtiter plates at a concentration of 0.15 X lo5 cells/well, giving a final volume of 200 pi/well. After 20 hr of incubation the cell growth was measured by the calorimetric MTT assay. Human rIL-1B (Glaxo, Geneva, Switzerland) was included as a standard. The detection limit of the assay was 15 pg rIL-l/ml supernatant.
Assay-for was determined by the IL&-dependent mouse hvbridoma cell line B13.29 clone B9 (Aarden et al.. 1987) . The cells were incubated in the presence of serially diluted samples, 'and growth measured after 72 hr using the MTT calorimetric assay. Human rIL-6 (Dr. L. Aarden, University of Amsterdam, The Netherlands) was used as standard. The detection limit of the assay was 15 pg/ml.
Assay for TNF. TNF was determined by its cytotoxic effect on the mouse fibrosarcoma cell line WEHI 164 clone 13 (Espevik and NisseenMeyer, 1986) . Cells were incubated with serial dilutions of test supernatants and viability was measured after 20 hr by a calorimetric assay based on a tetrazolium salt as previously described (Mosmann, 1983; Espevik and Nissen-Meyers, 1986) . Human recombinant TNF (Genetech, San Francisco, CA) was used as standard. The detection limit of the assay was 3 pg rTNFlm1 supernatant.
Microglia-and cytokine-supplemented MLR
To study the ability of microglia to reverse the nonpriming response by astrocytes, microglia, at nonpriming doses, were seeded into the MLR at either 1000 or 5000 cells oer well with the addition of CD4+ T cells. In some experiments human-rIL-lo (l-50 U/ml) (Genzyme), rIL-2 (50 U/ml) (Genzyme), rIL-6 (50 U/ml) (UBI, Lake Placid, NY), and rTNFo (50 U/ml) (UBI) were added to the glial-CD4+
T cell cocultures at the beginning of the assay. In subsequent experiments to neutralize IL-la activity, an IL-l receptor antagonist (IL-IRA) (Pepro Tech, Rocky Hill, NJ) (5-20 rig/ml) was added concurrently with rIL-la.
Results
Glial cell cultures As previously reported (Williams et al., 1992 (Williams et al., , 1993 , enriched human microglial cultures in excess of 95% Leu-MS+ cells were established (Fig. 1) . Microglia cultures established were Leu-M3-and nonspecific esterase-(NSE) distinguishing the microglia from peripheral blood monocytes that are Leu-M3+ and NSE+ (Williams et al., 1993; Ulvestad et al., 1994a) . The few contaminating cells in microglia cultures were GFAP-positive astrocytes. Fetal astrocyte cultures were similarly established with a high degree of purity (>95%) (Williams et al., 1993) , with contaminating cells being neuronal in origin ( Fig. 2A,B) . Adult human astrocytes could not be purified beyond 70% purity (Yong et al., 1991 ) and therefore could not be used in this study, which required more highly enriched cultures.
Antigen presentation assays Primary MLR. As seen in Figure 3 , titration studies showed that human-derived microglia were able to stimulate immediately ex vivo CD4+ T cells at seeding densities from 24 X lo4 cells per well. Em populations stimulated CD4+ T cells at E-concentrations starting at 2 X lo4 cells through 5 X IO4 cells per well. Human fetal astrocytes under basal culture conditions or following incubation with IFNy (100 U/ml, for 48 hr) did not stimulate freshly isolated CD4+ T lymphocytes in the allogenic MLR.
To test whether astrocytes cocultured with fresh CD4+ T cells provided any level of T cell stimulation, experiments were performed where human rIL-2 was added to astrocyte : CD4+ T cell cocultures. Figure 4 shows that the addition of human rIL-2 to astrocyte: CD4+ T cell cocultures resulted in CD4+ T cell proliferation, whereas the addition of rIL-2 to CD4+ T cells alone did not, indicating that astrocytes could stimulate CD4+ T cells to become IL-2 responsive. The magnitude of the CD4+ T cell proliferative response following addition of human rIL-2 was greater when astrocyte cultures had been prestimulated with IFNy (100 U/ml, 48 hr) prior to the addition of CD4+ T cells (Fig. 4) .
Secondary MLR. When freshly isolated CD4+ T lymphocytes, sensitized to fetal astrocyte cultures in vitro in the presence of rIL-2 for 5 d, were recovered, washed, and reintroduced to sister astrocyte cultures (2" MLR), a significant proliferative response was observed (Fig. 5 ). This response, indicating the ability of astrocytes to support the proliferation of previously activated CD4+ T cells, was not demonstrated using fresh CD4+ T cells from the same donor in a 1" MLR. The ability of astrocytes to support the continued proliferation of previously activated CD4+ T cells in a 2" MLR was partially inhibited by an anti-HLA-DR blocking antibody L243 (Fig. 5) . (1:300) for 30 min, and avidin-biotin-peroxidase complex (ABComplezVHRP) for 30 min. The colored reaction product was developed using 3-amino-9-ethyl-carbazole-containing buffer. Magnification, 300x. Cytokine gene and protein expression RT-PCR studies. Using RT-PCR, cDNA corresponding to IL-l (Y, IL-6, and TNFol was amplified from total microglial RNA isolated under basal tissue culture conditions, whereas cDNA corresponding to IL-6 was amplified from astrocyte RNA (Fig. 6) Figure 3 . Titration curve demonstrating stimulation of fresh allogeneic CD4+ T cells by microglia and nonrosetted peripheral blood-derived cells (E-), but not astrocytes. CD4+ T cells (1 X 105) were cocultured with irradiated astrocytes, microglia, and E-cells seeded at densities ranging from lo2 to 1 X 10s cells per well. Cultures were harvested on day 5 after a 5 hr pulse with 3H-TdR. Data points represent cpm k SEM of triplicate cultures. cpm of astrocytes, microglia, E-, and T cells alone was <900 (n = 2 experiments). Stimulator cell numbers on the x-axis = number X lo*. with IFN?, did not express detectable message for IL-lo or TNFo. The exclusive positive reaction product for IL-la and TNFol by microglia suggests that the reaction product was not the result of contamination by astrocytes in the microglial cultures. Similarly, the lack of IL-la and TNFo message by fetal astrocytes would argue against microglial contamination in the fetal astrocyte cultures.
Cytokine bioassays. Cytokine bioassays confirmed that microglia produce low levels of IL-I (6.7 pg/ml z!z 7 pg/ml) under basal culture conditions that increased following incubation with IFNy (72.2 pg/ml + 8.9 pg/ml). Microglia under basal culture conditions produced IL-6 (359 pg/ml -+ 50 pg/ml) and TNF (221 pg/ml + 28 pg/ml) that increased following IFNy stimulation (IL-6, 1401 pg/ml & 279) (TNR 1601 pg/ml + 45) (Fig.  7) . Human fetal astrocytes produced low IL-6 under basal culture conditions (30 pg/ml -t 12 pg/ml) that increased following IFNy stimulation (191 pg/ml 2 31 pg/ml). There were no detectable levels of IL-l or TNF by human fetal astrocytes under basal culture conditions or following IFNy stimulation (Fig. 7) .
Microglia
and cytokine supplement MLR. Using human r-cytokines, we investigated whether IL-l, IL-6, or TNF could provide a necessary secondary signal for astrocytes to present antigen in the MLR. As shown in Table 1 , the addition of human rIL-la (lo-50 U/ml) to astrocyte : CD4+ T cell cultures resulted in significant T cell proliferation in all but one experiment. In the experiment shown in Figure 2 , A and B, T cell proliferation occurred following the addition of 50 U/ml of IL-l to IFNystimulated astrocyte/T cell cocultures. In subsequent experiments, we were able to demonstrate CD4+ T cell proliferation using as little as 1 U/ml rIL-lo (Fig. 8) ; the maximal response was consistently observed following the addition of 10 U/ml . Cytokine production by adult human-derived microglia and fetal human-derived astrocytes in vitro. Data represent cytokine production by microglia and astrocytes seeded at a concentration of 4 X 104 cells per well. Cytokine production was assayed using 1 ml of conditioned supernatant from glial cells under basal culture conditions (solid bar) and following 1FN-y stimulation (hatched bar). Data represent the mean ? SEM pg/ml protein of triplicate wells (n = 2 experiments).
human rIL-1c-w (Table 1, Fig. 8 ). Human rIL-6 and rTNFa, used either separately or in conjunction with IL-la, did not augment CD4+ T cell proliferation beyond basal control levels or IL-1 (Yinduced levels, respectively (data not shown). Coincubation of fetal astrocyte:CD4+ T cell cocultures with human rIL-la (50 U/ml) and the IL-l receptor antagonist (IL-IRA) (5 rig/ml) inhibited the IL-l priming effect (26,715 2 7375 cpm vs 3258 ? 687 cpm) (n = 4 experiments).
To investigate whether microglia could provide a secondary signal to induce CD4+ T cell proliferation in the presence of nonstimulating astrocytes, microglia were seeded into the MLR at 1 X lo3 or 5 X lo3 cells per well; concentrations at which microglia alone did not induce proliferation in the MLR (Fig.  3) . As shown in Figure 9 , as few as 1 X 10" microglia seeded into the nonpriming MLR could effectively correct the inability of astrocytes to induce CD4+ T cell proliferation to the same amplitude or greater than the rIL-la control. Similar to the response with human rIL-2, the microglial-induced proliferation resulted in greater CD4+ T cell proliferation when fetal astrocytes were stimulated with IFNy prior to the addition of microglia and CD4+ T cells. The addition of the IL-1 RA (20 rig/ml) to astrocyte/microglia/T cell cocultures partially inhibited the reversal of the priming effect (47% inhibition) (n = 2 experiments). These data implicate the role of IL-l production by microglia in the induction of T cell responses, but also support the notion that additional accessory molecules expressed on microglia might be important in T cell activation.
Discussion
This study addresses whether and under what conditions astrocytes can function as APCs to initiate or perpetuate a CNS T cell-mediated immune response. The CNS has long been regarded as an immunologically privileged site based upon the belief that the CNS has a minimal number of cells expressing MHC class II antigens (Lampson et al., 1987) and that the CNS is inaccessible to circulating lymphocytes (Rapoport, 1976) . More recent studies have demonstrated that in the CNS immune surveillance does occur (Hickey et al., 1992; Lassmann et al., 1993) , MHC class II antigens are expressed in normal and diseased individuals (Sobel et al., 1984; Massa et al., 1986; Liu et al., 1989; Boyle and McGeer, 1990; Graeber et al., 1992; Sasaki and Nakazato, 1992; Nagra et al., 1993; Rinalso et al., 1994) , and an active immune regulation might be exerted (Cserr and Knoff, 1992) . Based upon initial observations of MHC class II expression in human inflammatory CNS disease and in EAE, astrocytes were the focus of early CNS antigen presentation studies. More recent evidence suggests that if MHC class II antigens are expressed on astrocytes, the level of class II is marginal or late in the disease, after significant inflammation has occurred (Sobel et al., 1984; Hickey et al., 1985; Matsumoto et al., 1986; Boyle and McGeer, 1990; Ulvestad et al., 1994b) . Additionally, in vitro models studying antigen presentation by rodent astrocytes have mainly utilized T cell lines Fierz et al., 1985; Massa et al., 1987) which are by definition previously activated cells, and therefore more accurately represent secondary T cell responses. In our study, fetal human astrocytes, in the absence of added cytokines, were unable to present antigen to freshly derived CD4+ T cells in a 1" MLR. Astrocytes were able to support CD4+ T cell proliferation in the presence of exogenous IL-2, suggesting that the astrocytes were able to stimulate lymphocytes to express IL-2 receptors and to become IL-2 responsive (Sprent and Schaefer, 1989) but not to produce IL-2 and to proliferate. Astrocytes were able to support the continued proliferation of CD4+ T cells previously sensitized to sister astrocyte cultures in a 2" MLR.
We have previously demonstrated that irradiated fetal human spleen cells, obtained from the same donor material as the astrocytes, were potent stimulators in the MLR, ruling out the inability of astrocytes to present antigen in the 1" MLR based on embryologic development (Williams et al., 1993) .
In addition to the requirement of class II expression for an APC to present antigen to MHC class II restricted CD4+ T cells, additional signals thought to be important in T cell activation include the immune accessory/adhesion molecules ICAM-1, LFA-3, and B7 (Altman et al., 1989; Linsley et al., 1990; Kaner et al., 1992) and accessory cytokine signals including IL-la, IL-6, and TNFa (Houssia et al., 1989; Vink et al., 1990) . We have previously demonstrated that fetal human astrocytes and adult human microglia could express similar adhesion molecules including MHC class II, LFA-3, and ICAM-1, though microglia consistently expressed higher levels of these molecules (Williams et al., 1993) . Microglia also were positive for LFA-1 and B7-BBl, the latter being more markedly expressed following induction with IFNy (Williams et al., 1993 ). In the current report we further investigated the inability of fetal human astrocytes, a non-hematopoietic, MHC class II&x-pressing cell, to stimulate CD4+ T cells in an MLR; in particular, we compared cytokine production by astrocytes and microglia. Our data for adult human microglia cytokine production is consistent with previous reports for rodent (Giulian et al., 1986; Hetier et al., 1988; Woodroofe et al., 1991) and human (Aloisi In some experiments IL-la (10 U/ml) or irradiated microglia (103) (MG) were added to astrocyte: CD4+ T cell cocultures. Cultures were harvested on day 5 after a 5 hr pulse with 3H-TdR. cpm of astrocytes, astrocytes plus microglia, or CD4+ T cell with rh IL-1 was <900. Results presented here are representative of n = 4 experiments. Lee et al., 1993; Sebire et al., 1993) fetal microglial cultures. Cytokine production by astrocytes is not resolved and remains controversial (Hetier et al., 1988; Sebire et al., 1993) . Similar to previous reports using fetal human- (Aloisi et al., 1992; Lee et al., 1993; Sebire et al., 1993) and rodent-derived astrocytes (Heitier et al., 1988) , we did not detect IL-la message or protein in our purified fetal astrocyte cultures under basal culture conditions or following IFNy stimulation. We did demonstrate IL-6 mRNA and production by human fetal astrocytes, as have others (Vitkovic et al., 1991; Lee et al., 1993) . Others have, however, reported the synthesis of IL-l by rodent astrocytes or astrocyte cell lines (Fontana et al., 1982 (Fontana et al., , 1983 Fontana and Grob, 1984) . Similarly, there are reports of TNFcx mRNA and protein production by human (Lee et al., 1993) and rodent astrocytes following viral infection or induction with IL-ll3 or LPS (Lieberman et al., 1989; Sawada et al., 1989) . Our data indicating a lack of IL-lo production by human fetal astrocytes is supported by our functional data demonstrating that recombinant human IL-1 (Y could reverse the inability of astrocytes to stimulate T cells in the MLR. In situ, IL-l has been shown to be elevated in a rodent CNS injury model (Woodroofe et al., 1991) , in MS serum and CSF (Hofmann et al., 1986; Tsukawda et al., 1991) , and in the CNS of HIV-infected individuals (Tyor et al., 1992) . The reversal of the inability of astrocytes to present in the MLR by the addition of exogenous IL-l was blocked with an IL-l RA. The IL-1 RA has been shown to abrogate symptoms in animal models of autoimmune disease (Dinarello et al., 1991) and has been used to inhibit the induction of EAE (Jacobs et al., 1991) . The inability of the IL-1RA to completely inhibit T cell proliferation when microglia were seeded with astrocyte cultures might be due to microglia phagocytosis of the receptor antagonist;
alternatively, these data indicate the possibility of additional microglial signals including B7/BB-1 or ICAM- (Altmann et al., 1989) contributing to T cell activation. We have not ruled out that the IL-l effect might be acting directly on the astrocytes (Lee et al., 1993) .
IL-1 has been previously demonstrated to be a necessary secondary signal provided by a variety of APC, including macrophages (DeFreitas et al., 1983; Kurt-Jones et al., 198.5) , monocytes (Scala et al., 1988) , and B cells (Chu et al., 1985) , to initiate or perpetuate T cell activation.
IL-l has also been shown to function as an autocrine cytokine for T cell proliferation (Tartakousky et al., 1988) , to be essential for TH2 costimulation (Weaver et al., 1988; Zubiaga et al., 1991) , and to be involved in the priming response by dendritic cells (Koide et al., 1989; Enk and Katz, 1992 ). Since we found that both microglia and astrocytes produce IL-6, we cannot rule out the possibility that the IL-la response may be functioning in cooperation with astrocyte-produced IL-6 (Holsti and Raulee, 1989) . The type of cells that can stimulate CD4+ T cell proliferation in an MLR remains controversial.
A variety of class IIexpressing, hematopoietic cells have been reported to function as APCs. These cells include B cells, endothelial cells, dendritic cells, and macrophages (Sprent et al., 1989) . T cell contact with MHC class II antigens on nonhematopoietic cells such as astrocytes usually results in CD4+ T cell tolerance and not T cell proliferation (Miller et al., 1991) . Matsumoto et al. (1992) have recently described that rodent astrocytes in vitro, under in situ mimicking conditions, do not stimulate T cells; instead, the presentation of antigen to T cells by astrocytes results in the inactivation of T cells. In the current study, microglia at very low cell numbers were able to reverse the inability of astrocytes to present antigen in the 1" MLR. Recently it has been shown that the ligation of CD28 on T cells by B7 can inhibit or reverse the induction of T cell anergy (Harding et al., 1993) . This might provide an alternative mechanism of microglial stimulation in our assay system where B7/BB-1 expression on microglia might function to inhibit the induction of anergy by astrocytes. In our assay system, highly enriched cultures of human fetal astrocytes were not able to present antigen in the MLR, but could stimulate CD4+ T cells following the addition of as little as 1 U/ml of rIL-la or by the addition of a small number of microglia.
Our data support the notion that, in vitro, astrocytes are poor APCs. Our data raise the interesting possibility that astrocytes in situ, with the help of an accessory cell providing either a soluble secondary signal or the surface expression of accessory molecules, might effectively stimulate T cell proliferation, thereby initiating or perpetuating a CNS immune event. These data might be of particular relevance in the inflamed CNS of MS or HIV-infected individuals where increased MHC class II expression and IL-1 production has been demonstrated.
